Novo Holdings REPAIR Impact Fund invests USD12m in Mutabilis and IBT Vaccines

  07 January 2020

The Novo Holdings REPAIR Impact Fund has made a EUR7 million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections based near Paris, France. 

This investment will allow the company to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimisation.

Further reading: PrivateEquityWire
Author(s): PrivateEquityWire
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed